Johnson & Johnson charts signal potential pharma breakout as sector momentum strengthens

Traders Union
All News
Financial News
Johnson & Johnson pharma breakout

Highlights

The iShares U.S. Pharmaceuticals ETF (IHE) hit new highs on weekly MACD crossover, reflecting broadening sector leadership and outperformance potential versus SPX.
Eli Lilly drives IHE gains by holding roughly 25% of fund assets, but price action and moving averages indicate growing participation across the pharma sector.
Johnson & Johnson shows technical breakout potential with stochastics and MACD turning bullish, support at $213, resistance at $249, and a relative uptrend versus SPX into 2025.

Sector momentum points to broader pharma participation

As reported by CNBC, strength in pharmaceutical stocks is extending beyond a single company as the iShares U.S. Pharmaceuticals ETF, or IHE, pushes to new highs and confirms its cyclical uptrend with a weekly MACD crossover.

Eli Lilly remains a major driver of the group and accounts for roughly 25% of IHE, making its breakout to all-time highs a meaningful tailwind for the fund. But the ETF's advance also suggests sector leadership is widening, while the ratio of IHE to the SPX is rebounding from support at its 200-day, or 40-week, moving average, indicating potential for further outperformance in the coming weeks.

The longer-term relative setup also remains constructive because the 40-week moving average continues to slope higher. That trend supports the view that pharma is improving in both absolute and relative terms within the U.S. equity market.

Johnson & Johnson setup sharpens near key levels

Johnson & Johnson is also showing signs of renewed strength after a period of consolidation, with weekly stochastics turning up from oversold levels and the weekly MACD histogram posting consecutive gains. Those signals often align with an intermediate-term low and suggest the stock could reassert leadership within the pharma group.

From a price-level perspective, initial support is marked by the rising 200-day moving average near $213, while resistance stands near the highs around $249. On the daily chart, JNJ also has an active countertrend buy signal from DeMARK Indicators®, and the daily MACD has returned to a buy signal as the stock moves back above its 50-day moving average and into the daily cloud.

The relative picture adds to the bullish case. The JNJ versus SPX ratio has been in a countertrend cyclical upmove since the beginning of 2025, marked by a series of higher lows, and it now approaches support at its 40-week moving average from an oversold position, leaving the shares at what the analysis describes as a relative proving ground for another move higher.

In our earlier article on Eli Lilly’s rally and outlook, we covered how the stock pushed higher on upbeat updates to its weight-loss drug pipeline and remained firmly above key moving averages. We also noted that while one institution trimmed its stake, the broader read-through stayed constructive, with momentum indicators pointing to consolidation at elevated levels and an increased probability of another upside breakout.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.